Company profile: Advanced Accelerator Applications
1.1 - Company Overview
Company description
- Provider of targeted radioligand therapies and precision imaging radioligands, offering LUTATHERA: a radioligand therapy using lutetium Lu 177 dotatate for treating tumors; PLUVICTO: a therapeutic radioligand containing lutetium Lu 177 vipivotide tetraxetan; diagnostic PET imaging kits NETSPOT, LOCAMETZ, and SOMAKIT TOC; and LysaKare to reduce renal radiation exposure during peptide-receptor radionuclide therapy with LUTATHERA.
Products and services
- PLUVICTO®: AAA produces a targeted therapeutic radioligand product containing lutetium Lu 177 vipivotide tetraxetan, delivering Lu‑177–based treatment through radioligand administration for therapeutic use
- LUTATHERA®: AAA delivers a targeted radioligand therapy using lutetium Lu 177 dotatate for treating tumors, offering Lu‑177–based therapeutic administration via radioligand technology
- LOCAMETZ®: AAA supplies a diagnostic kit for preparing gallium Ga 68 gozetotide injection for diagnostic use, enabling Ga‑68–labeled radioligand preparation for diagnostic workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Advanced Accelerator Applications
Oncoceutics
HQ: United States
Website
- Description: Provider of drug discovery and development targeting the most potent suppressor pathways in human cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncoceutics company profile →
H-Immune
HQ: France
Website
- Description: Provider of early-stage biopharmaceutical research and development, utilizing an immunotherapeutic approach to create novel, fully human antibody-based blockade therapeutics aimed at generating new immuno-oncology treatments for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full H-Immune company profile →
Peptomyc
HQ: Spain
Website
- Description: Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptomyc company profile →
Insure One
HQ: United States
Website
- Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insure One company profile →
PharmaMar
HQ: Spain
Website
- Description: Provider of oncology medicines inspired by the sea, discovering antitumor molecules from marine organisms through integrated research and development. Delivers innovative products to equip healthcare professionals with new tools to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaMar company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Advanced Accelerator Applications
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Advanced Accelerator Applications
2.2 - Growth funds investing in similar companies to Advanced Accelerator Applications
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Advanced Accelerator Applications
4.2 - Public trading comparable groups for Advanced Accelerator Applications
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →